Find, compare & contact
Sutimlimab API Manufacturers & Suppliers

General Description:

Sutimlimab, identified by CAS number 2049079-64-1, is a notable compound with significant therapeutic applications. Cold agglutinin disease (CAD) is a type of autoimmune hemolytic anemia (AIHA) in which autoantibodies directed against red blood cell surface antigens cause hemolysis at low (3-4°C) temperatures. This cold subtype accounts for approximately 15-25% of all AIHA and is more common in the elderly. In approximately 90% of cases, patients develop immunoglobulin M (IgM) autoantibodies towards the I antigen on erythrocytes - these antibodies react optimally at 4°C and are therefore referred to as "cold agglutinin". Hemolysis in patients with CAD is driven by complement activation, which initiates a cascade that ultimately leads to both intra- and extravascular hemolysis. The most common presenting symptoms in patients with CAD are chronic anemia, acrocyanosis, and Raynaud phenomenon. Treatment options for patients with CAD are limited. In addition to non-pharmacological strategies, such as counseling patients to keep warm and the use of red blood cell transfusions, approximately 70% of patients require pharmacological treatment. Pharmacologic strategies have included the targeting of B-cells with agents like , as well as targeting of the complement system with drugs like , an anti-C5 mAb, and , a novel inhibitor of C3. Notably, none of these agents are approved for use in the treatment of CAD. Sutimlimab is a first-in-class humanized monoclonal antibody targeted at complement subunit C1s, which is responsible for activating the classic complement pathway. It received FDA approval in February 2022, under the brand name Enjamyo (sutimlimab-jome), becoming the first approved therapy for patients with CAD. Sutimlimab was also approved by the European Commission in November 2022.

Indications:

This drug is primarily indicated for: Sutimlimab is indicated to decrease the need for red blood cell transfusion due to hemolysis in adult patients with cold agglutinin disease. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Sutimlimab undergoes metabolic processing primarily in: As with other therapeutic proteins, sutimlimab likely undergoes catabolism to smaller peptides and amino acids. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Sutimlimab are crucial for its therapeutic efficacy: When administered at the approved weight-based recommended dosage, the exposure to sutimlimab increases proportionately with increasing dosage. Steady-state concentrations are achieved by week 7 of therapy. The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Sutimlimab is an important consideration for its dosing schedule: At the approved recommended dosage, the terminal elimination half-life of sutimlimab is 21 days. The half-life of sutimlimab varies at different doses due to target-mediated drug disposition at lower concentrations. This determines the duration of action and helps in formulating effective dosing regimens.

Volume of Distribution:

Sutimlimab is distributed throughout the body with a volume of distribution of: At steady-state, the volume of distribution of sutimlimab in patients with cold agglutinin disease was approximately 5.8 L. This metric indicates how extensively the drug permeates into body tissues.

Clearance:

The clearance rate of Sutimlimab is a critical factor in determining its safe and effective dosage: At the approved recommended dosage, the clearance of sutimlimab is 0.14 L/day. The clearance of sutimlimab varies at different doses due to target-mediated drug disposition at lower concentrations. It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Sutimlimab exerts its therapeutic effects through: Following a single sutimlimab injection, >90% inhibition of the complement pathway was observed, and this inhibition was sustained when concentrations of sutimlimab were ≥100 mcg/mL. As sutimlimab can impair the complement-mediated immune response, patients requiring therapy should receive all appropriate vaccinations against encapsulated bacteria at least 2 weeks prior to its initiation. Patients undergoing treatment with sutimlimab are at a higher risk of serious infections, especially those caused by encapsulated bacteria such as _Neisseria meningitides_ or _Streptococcus pneumoniae_, and should be monitored closely throughout therapy for evidence of developing or ongoing infections. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Sutimlimab functions by: Hemolysis associated with cold agglutinin disease is driven by the activation of the complement system. Cold agglutinins transiently bind erythrocytes as they circulate through cooler parts of the body (e.g. the extremities) - as they circulate back to warmer areas, C1q esterase activates C4 and C2, which generates C3 convertase, an enzyme which cleaves C3 into C3a and C3b. At this stage, the erythrocytes tagged with C3b can be sequestered by macrophages in the reticuloendothelial system, ultimately leading to extravascular hemolysis. Alternatively, C3b may be further cleaved into C3c and C3d - if complement activation continues past the C3 step, the membrane attack complex with C5b-C9 may form, which causes intravascular hemolysis. Sutimlimab is a humanized IgG4 monoclonal antibody targeted at the complement C1s subunit, a serine protease responsible for the activation of the classic complement pathway. By inhibiting the complement cascade at the level of C1s, sutimlimab prevents the deposition of complement opsinins on erythrocytes, thus preventing their eventual hemolysis. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Classification:

Sutimlimab belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.

Categories:

Sutimlimab is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Antibodies, Antibodies, Monoclonal, Antineoplastic and Immunomodulating Agents, Blood Proteins, Classical Complement Pathway Inhibitor, Globulins, Immunoglobulins, Immunoproteins, Immunosuppressive Agents, Proteins, Selective Immunosuppressants, Serum Globulins. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Experimental Properties:

Further physical and chemical characteristics of Sutimlimab include:

• Molecular Weight: 147000.0
• Molecular Formula: C6436H9934O2012N1700S46